Shimadzu Releases New Protein Sequencer for Biopharma QC

Shimadzu has released the PPSQ-51A/53A SPD-40 model protein sequencer, an automated platform for amino acid sequence analysis aimed at the quality control of antibody and peptide drugs. Announced on 19 June 2026 for Japan and overseas markets, the system runs all steps from sample loading through to amino acid sequence prediction automatically. Shimadzu remains the only company in the world manufacturing and selling protein sequencers commercially.

The system uses Edman degradation to sequentially cleave the N-terminus of proteins, with cleaved amino acids analysed by liquid chromatography to determine the sequence. That capability is increasingly relevant to manufacturers of antibody drugs and peptide drugs, where amino acid sequence integrity directly affects target specificity, efficacy and safety. The PPSQ-51A/53A integrates Edman degradation, LC analysis and sequence estimation in a single workflow, ensuring consistent results regardless of operator skill level. LabSolutions PPSQ control software handles the analytics layer, while the LabSolutions DB/CS database supports data integrity compliance requirements.

Shimadzu has been developing protein sequencers for 40 years and frames the new release as part of its broader strategy under a new medium-term management plan focused on the life science market. The company will continue to expand product lines designed to deliver core analytical capability for R&D and quality control across pharmaceuticals and food applications. The detector design has been tuned for maintainability and data stability, both of which matter most in routine QC environments where instrument downtime carries direct commercial cost.

The strategic logic is straightforward. With antibody and peptide therapeutics becoming an ever-larger share of biopharma pipelines, demand for amino acid sequence verification in routine quality control is structurally rising. Shimadzu’s sole-supplier position in commercial protein sequencers gives it a strong defensible niche, particularly as biologics manufacturing capacity continues to expand across Japan, Korea, China and emerging Indian biopharma.

For the latest updates and in-depth insights into the world of Service Engineering, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!